NHE3 reabsorve a maior parte de Na+ em túbulos proximais e é agudamente modulado por Ang II de forma bimodal. O objetivo deste trabalho foi avaliar os efeitos crônicos da Ang II sobre a atividade, expressão e atividade promotora de NHE3. A atividade de NHE3 foi avaliada na presença de veículo, inibidor de NHE1, 2 e 3 e H+ ATPase. Houve redução da recuperação do pHi na presença do inibidor de NHE3. Células foram expostas por 24h a Ang II de 10-7M a 10-12 M e houve aumento de atividade com Ang II 10-11 M. Houve aumento na expressão de NHE3 e no seu RNAm. Actinomicina D não mostrou diferença entre os tempos de ½ vida do RNAm. Transfecções transitórias de fragmentos do promotor de NHE3 de rato mostraram que a atividade do fragmento -65/+31 aumentou na presença de Ang II. Mutações em sítios para a ligação de Sp1/Egr-1 e AP2 mostraram que o sítio Sp1/Egr-1 é fundamental para esse efeito. As vias que envolvem o citocromo P450, PI3K, PKA e MAPK são ativadas, porém, as vias da PLC e JAK/STAT não. Losartan aboliu os efeitos observados. Conclui-se que a exposição crônica à baixa concentração de Ang II promoveu aumento na atividade, expressão, nível de RNAm e atividade promotora do gene NHE3 via AT1R. O sítio de ligação para os fatores de transcrição Sp1/Egr-1 está envolvido nessa resposta. / NHE3 is the major responsible for the sodium reabsorption in proximal tubules and it is Ang II acutely modulated in a bimodal fashion. The aim of this study was to evaluate the chronic effects of Ang II on NHE3 activity, transcription and expression. The NHE3 activity was evaluated in the presence of vehicle, NHE1, 2 and 3 and H+ ATPase inhibitors. Presence of NHE3 inhibitor reduced the rate of pHi recovery. Cells were treated with Ang II 10-7M to 10-12 M for 24h and Ang II 10-11 M increased the pHi recovery rate. NHE3 protein and mRNA were increased in Ang II presence. NHE3 mRNA ½ life in Actinomycin D incubated cells was not affected by Ang II treatment. Transient transfections of fragments of rat NHE3 promoter showed that the activity of -65/+31 was increased in Ang II presence. Mutation at Sp1/Egr-1 and AP2 sites in the -60/+31 fragment showed that Sp1/Egr-1 integrity is required. Cytochrome P450, PI3K, PKA and MAPK signaling pathways are related with this effect, while PLC and JAK/STAT are not. Losartan abolished the observed effects. In conclusion, chronic treatment with low concentration of Ang II resulted in increase of NHE3 activity, protein expression, mRNA levels and promoter activity of NHE3 gene through AT1R. Sp1/Egr-1 site seems to be involved in this effect.

Orientadores: Nicola Amanda Conran Zorzetto, Fernando Ferreira Costa / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-25T23:15:59Z (GMT). No. of bitstreams: 1 Santos_AlissonFernandesdos_D.pdf: 3501020 bytes, checksum: 082754f565197f1a75d8da113de08ea3 (MD5) Previous issue date: 2014 / Resumo: A anemia falciforme (AF) é uma doença genética causada pela substituição de um ácido glutâmico por uma valina na posição 6 da cadeia globina 'beta'. A mutação de ponto origina a hemoglobina S (HbS), que sob condições de deoxigenação se polimeriza tornando os eritrócitos mais propensos à falcização. A fisiopatologia da AF resulta em processos recorrentes de vaso-oclusão e hemólise, causando numerosas complicações clínicas, incluindo a danificação dos rins e problemas cardiovasculares. A angiotensina II (Ang II), um peptídeo vasoconstritor derivado do sistema renina-angiotensina (SRA), controla a pressão arterial e o equilíbrio dos fluidos. A Ang II também participa na geração de espécies reativas de oxigênio, diminuindo a biodisponibilidade do óxido nítrico (NO), um gás vasodilatador, podendo contribuir para alterações no endotélio. A hidroxiureia (HU), agente quimioterápico importante no tratamento dos indivíduos portadores de AF, exerce seu efeito benéfico por meio do aumento de hemoglobina fetal (HbF), reduzindo a falcização dos eritrócitos, diminuindo o número de leucócitos, além de possuir a capacidade de gerar NO. O objetivo deste estudo foi verificar se a produção e expressão das proteínas do SRA estão alteradas na AF e os efeitos da terapia com HU nestes parâmetros. Para analisar a atividade do SRA na AF e um possível papel para a Ang II no processo inflamatório, foram quantificadas as concentrações plasmáticas de Ang II, enzima conversora de angiotensina (ACE), molécula de adesão vascular-1, molécula de adesão intercelular-1, endotelina-1 (ET-1), metabólitos de NO, guanosina monofosfato cíclico (GMPc), interleucina-6, interleucina-8, fator de necrose tumoral-'alfa' e inibidor do ativador do plasminogênio-1 nas amostras de sangue dos indivíduos portadores de AF e indivíduos sadios controles. A produção de Ang II e expressão de algumas proteínas do SRA também foram estudadas em um modelo animal de AF. Adicionalmente, camundongos com AF foram tratados com a HU (50 e 75 mg/kg/dia) por 4 semanas. Não foram encontradas diferenças significativas nos níveis plasmáticos de Ang II nos indivíduos portadores de AF e indivíduos controles, porém a Ang II mostrou correlação positiva com níveis plasmáticos de HbF e ET-1. Uma correlação negativa entre níveis da Ang II e GMPc também foi encontrada no plasma. As concentrações plasmáticas de ACE foram encontradas significantemente menores em indivíduos portadores de AF em comparação aos indivíduos controle. Em camundongos com AF, as concentrações plasmáticas de Ang II estão significativamente diminuídas quando comparadas aos camundongos controles. O tratamento de camundongos AF com HU (75 mg/kg/dia) aumentou significativamente os níveis de Ang II. Diferenças significativas nas expressões dos genes AT1R e ACE1 (que codificam o receptor de angiotensina II tipo 1 e a enzima ACE, respectivamente) foram detectadas em camundongos com AF sem tratamento de HU quando comparados aos camundongos controles, sendo que as expressões dos genes foram menores nos rins e maiores no fígado. Os dados obtidos no estudo sugerem que pode haver alterações no SRA em indivíduos portadores de AF, apesar de não encontrar associações entre alterações em Ang II com parâmetros inflamatórios. Futuros estudos poderiam indicar se alterações na expressão das proteínas do SRA contribuem para algumas manifestações da AF ou refletem danos teciduais nestes indivíduos / Abstract: Sickle cell disease (SCD) is caused by a point mutation that results in the substitution of glutamic acid for valine at the sixth position of the 'beta'-globin chain, leading to the production of hemoglobin S (HbS). HbS polymerizes under conditions of low oxygen concentration, causing the erythrocyte to adopt a sickled shape. The pathophysiology of SCD results in recurrent vaso-oclusion and hemolysis, causing clinicals complications, including kidney damage and cardiovascular problems. Angiotensin II (Ang II), a peptide and vasoconstrictor derived from the action of the renin-angiotensin system (RAS), controls blood pressure and fluid balance. Ang II also participates in the generation of reactive oxygen species, decreasing the bioavailability of the vasodilatory gas nitric oxide (NO), and potentially causing endothelial alterations. Hydroxyurea (HU), an important chemotherapeutic drug employed in the treatment of SCD, has numerous benefits that include augmentation of fetal hemoglobin, reduction of erythrocyte sickling and decreased leukocyte numbers; furthermore, HU also generates NO in vivo. The aim of this study was to investigate whether the production and expression of proteins of the RAS are altered in SCD and the effects of HU therapy on these parameters. To analyse alterations in Ang II and possible associations with inflamatory processes in sickle cell anemia (SCA), the following were quantified in the plasma of SCA patients on and off HU and in healthy control individuals; Ang II, angiotensin converting enzyme (ACE), vascular adhesion molecule-1, intercellular adhesion molecule-1 and endothelin-1 (ET-1), NO metabolites, cyclic guanylate monophosphate (cGMP), interleucin-6, interleucin-8, tumor necrosis factor-'alfa' and plasminogen activator inhibitor-1. The production of Ang II and the expressions of some RAS proteins were also studied in an animal model of SCD. In addition, SCD mice were treated, or not, with hydroxyurea (50 and 75 mg/kg/day) for 4 weeks. Plasma levels of Ang II of SCA patients did not differ from those of controls; however, Ang II demonstrated positive correlations with fetal hemoglobin and ET-1; and a negative correlation with plasma cGMP. Plasma levels of ACE were significantly lower in SCA individuals compared with control individuals. In SCD mice, plasma levels of Ang II were significantly decreased when compared to control mice. Treatment with HU (75 mg/kg/day) in the SCD mice increased levels of Ang II significantly. Significant differences in the gene expressions of AT1R and ACE1 (encoding the angiotensin II receptor type 1 and ACE) were detected in SCD mice not treated with HU, when compared to control mice, where these gene expressions were lower in the kidneys and higher in the liver. These results suggest that some alterations in the RAS may occur in SCD individuals. Although we found no association between plasma Ang II levels with inflammatory parameters in patients, further studies should indicate whether alterations in the RAS may contribute to some of the manifestations of SCD or reflect tissue damage in these individuals / Doutorado / Clinica Medica / Doutor em Clínica Médica

Conselho Nacional de Desenvolvimento Científico e Tecnológico / The objective of this study was to investigate the factors controling the expression of angiotensin II (AngII) receptors and to determine the physiological role of AngII in granulosa cells. The AGTR2 receptor was localized in granulosa (and theca) cells from follicles of different sizes. Bovine ovaries were collected at a local abattoir and small follicles (2-5mm) were isolated for harvesting granulosa cells. The cells were cultured in free medium serum in non-luteinizing conditions without FSH (control group) or with graded doses of FSH or IGF1. In other cultures, cells were cultured with or without IGF1 and bone morphogenetic protein-7 (BMP-7), and fibroblast growth factor-2 (FGF-2). Treatment with FSH, IGF1 and BMP-7 increased (P<0.05) estradiol secretion and AGTR2 mRNA expression relative to control cultures. In contrast, none of these treatments affected AGTR1 receptor expression. Addition of FGF-2 significantly decreased estradiol secretion but did not affect AGTR1 or AGTR2 expression. Cells were cultured with FSH plus graded doses of FGF-7 or FGF-10, and the effects of these factors on AGTR2 protein levels were measured by Western blot. AGTR2 protein levels decreased in the groups treated with FGF-7 (10 and 100ng/ml) and FGF-10 (all concentrations; P<0.05), and estradiol secretion was significantly inhibited by the highest dose of each FGF (P<0.05). Bovine follicles greater than 5 mm diameter were dissected and granulosa and theca cells were separated for RNA extraction, and follicle fluid assayed for estradiol (E2) and progesterone (P) content. Non-atretic follicles (P less than 100ng/ml) were classed as estrogenic (E2 greater than 100ng/ml) or non-estrogenic (E2 less than 40ng/ml). There were no differences in AGTR1 receptor expression in theca and granulosa cells between estrogenic and nonestrogenic follicles. Likewise, there were no changes in AGTR2 receptor expression in theca cells with follicle state. However, AGTR2 receptor mRNA levels were significantly higher in granulosa cells of estrogenic compared to non-estrogenic follicles (P<0.01), and AGTR2 receptor mRNA was correlated with E2 concentrations in follicular fluid. To determine the physiological consequences of AT activation in granulosa cells, cells from small (2-5mm) bovine follicles were cultured in serum-free medium with FSH ± AngII. The addition of AngII had no effect on estradiol or progesterone secretion, but significantly inhibited protease nexin-1 (PN-1) mRNA levels and protein secretion (P<0.05). PN-1 is an inhibitor of proteases involved in extracellular matrix remodeling and follicle rupture. Bovine granulosa cells from large (>10 mm) follicles were cultured for 6h, 12h and 24h with LH (100ng/ml) or AngII, with or without angiotensin receptor blocker (losartan for AGTR1 and PD123,319 for AGTR2). These cells expressed Ptgs2 under basal culture conditions, which was not upregulated by either LH or AngII alone. However, LH and AngII in combination significantly enhanced Ptgs2 (P<0.05) mRNA and protein accumulation. Similarly, expression of the proteolytic enzymes uPA and tPA, and their inhibitor, PN-1, were upregulated by the combination of LH and AngII but not by either factor alone. The addition of AGTR blockers inhibited the effect of AngII. In conclusion, AGTR2 receptor is present in granulosa bovine cells, and mRNA and protein are regulated by FSH, IGF-1, BMP-7, FGF-7 and FGF-10 in bovine granulosa cells in vitro, AGTR2 but not AGTR1 receptor mRNA levels are regulated during follicular growth in cattle, and that AngII regulates granulosa PN-1 secretion. These data suggest that AngII is a physiological co-factor necessary for the expression of genes in granulosa cells that are critical for ovulation. / O objetivo deste trabalho foi estabelecer o controle de expressão dos receptores de angiotencina II (AngII) e determinar a ação fisiológica da AngII em células da granulosa (CG) cultivadas in vitro. Os receptores de AngII tipo 1 (AGTR1) e tipo 2 (AGTR2) foram localizados em folículos de bovinos de diferentes tamanhos. Verificouse que as CG de bovinos provenientes de folículos entre 2- 5 mm e cultivadas com FSH, IGF-1, BMP-7 apresentaram aumento na expressão do receptor AGTR2 (P<0,05) em relação ao grupo controle (GC), bem como aumento da secreção de estradiol (E2; P<0,05). Em contraste, as CG tratadas com 10 ng/ml de FGF-2 ou 10 e 100 ng/ml de FGF-7 e FGF-10 apresentaram uma redução na secreção de E2 (P<0,05), porém somente os grupos FGF-7 e 10 nas doses 10 e 100 ng/ml reduziram (P<0,05) a expressão do receptor AGTR2. Para os dois experimentos, não houve diferença na expressão do receptor AGTR1 entre o GC e os grupos tratados. As CG e células da teca (CT) foram coletadas de ovários provenientes de abatedouro para extração de RNA e o fluido folicular para dosagem de E2 e progesterona P4. Esses folículos foram classificados como dominantes (FD; P4<100ng/ml e E2>100ng/ml) e atrésicos (FA; P4>40ng/ml). A expressão dos receptores AGTR1 e AGTR2 foi mensurada por RTPCR. Não houve diferença na expressão do receptor AGTR1 entre FD e FA. No entanto, o receptor AGTR2 apresentou um aumento (P<0,05) na expressão em CG de FD em relação a FA. A expressão do receptor AGTR1 se manteve constante em CG e CT de FD e FA. Para determinar os afeitos da AngII através da ativação de seus receptores CG foram cultivadas em meio livre de soro com FSH e/ou AngII. A AngII não apresentou efeito na secreção de E2 ou P4, mas inibiu (P<0.05) mRNA e proteína para a protease nexin-1 (PN-1). Considerando a redução de expressão da PN-1 envolvida no controle do remodelamento da matriz extracelular (RME), é possível especular um efeito de AngII sobre RME durante o desenvolvimento folicular. Em um terceiro experimento, as CG de folículos grandes (>10mm) foram cultivadas durante 6h, 12h e 24h na presença de Ang (10-5) com ou sem LH (100ng/ml). A combinação de AngII e LH aumentou significativamente (P<0,05) a expressão de mRNA e proteína para COX-2, ativador do plasminogênio tipo U e T, bem como para PN-1. Entretanto, AngII ou LH não aumentaram a expressão de COX-2. O aumento da expressão destes gene indica uma função de AngII no processo de ovulação através das CG. Em um segundo momento, verificou-se através de qual receptor a AngII atua para controlar a expressão desses genes. As CG foram cultivadas por 6h com LH e/ou AngII com ou sem inibidores específicos para o receptor AGTR1 (losartan) e AGTR2 (PD123,319). Os resultados demonstraram que a presença do inibidor de AGTR2 bloqueou o efeito da associação de LH e AngII em relação ao grupo controle (P<0.05), demonstrado que a ação da AngII é mediada pelo receptor AGTR2 em CG. Em conclusão, o receptor AGTR2 está presente nas células da granulosa de bovinos e o mRNA para o receptor AGTR2 é regulado durante o crescimento folicular. Além disso, a expressão do mRNA e a tradução da proteína para o AGTR2 são reguladas por FSH, IGF-1, BMP-7, FGF-7 e FGF-10 em CG de bovinos cultivadas in vitro. Os dados também sugerem que AngII regula a proteína PN-1 em CG e age como um co-fator fisiológico necessário para a ovulação.

La signalisation purinergique participe à de nombreux processus physiopathologiques dans le système cardiovasculaire. Alors que les nucléotides extracellulaires sont considérés comme des « signaux de danger » ; la NTPDase1(CD39), ectonucléotidase à l’origine de leur hydrolyse, permet de maintenir l’homéostasie vasculaire par ses actions anti-thrombotiques etimmuno-modulatrices. Le rôle de CD39 dans la fonction vasculaire liée à l’hypertension artérielle(HTA) reste méconnu. L’HTA, facteur de risque majeur de complications cardiovasculaires, est caractérisée par un remodelage structurel(hypertrophie, fibrose) et fonctionnel (hypercontractilité, dysfonction endothéliale) des vaisseaux, causées notamment par un stress oxydatif et une inflammation périvasculaire. L’objectif de notre projet a consisté à étudier l’évolution de CD39 ainsi que son rôle potentiel dans la condition vasculaire pathologique de l’HTA. Nous mettons en évidence une diminution de l’expression et de l’activité du CD39 vasculaire dans l’HTA. Une diminution de l’activité ADPase du CD39 soluble a également été observée au niveau circulant. L’étude des éléments à l’origine de cette diminution montre une sensibilité du transcrit vasculaire de CD39 à certaines cytokinespro- et anti-inflammatoires, mais également à une tension mécanique. Une étude in vivo du potentiel rôle de CD39 (souris déficientes pour le gène de CD39 (Entpd1) et traitement à l’apyrase) dans un modèle d’HTA à l’Angiotensine-II a également été réalisée. L’ensemble de ces données suggère qu’une diminution du CD39 vasculaire et circulant pourrait contribuer à majorer les altérations vasculaires contemporaines de l’HTA. / Purinergic signaling is involved in numerous physiopathological processes in cardiovascular system. While extracellular nucleotides are considered as « danger signals » ; the NTPDase1(CD39), ectonucleotidase responsible for their hydrolysis, preserves vascular homeostasis by itsanti-thrombotic and immunomodulatory actions.The role of CD39 in vascular function related to arterial hypertension remains unknown. Hypertension, the major risk factor of cardiovascular complications, is characterized by structural remodeling (hypertrophy, fibrosis) and functional (hypercontractility, endothelial dysfunction) of vessels caused in particular by perivascular oxidative stress and inflammation.Our aim was to investigate the evolution of CD39 expression / function and its potential contribution in the pathological vascular condition of hypertension. We highlighted a decrease invascular CD39 expression and activity in the context of hypertension. A decrease in soluble ADPase activity specific to CD39 was also observed in blood circulation. Investigation of elements responsible for this decrease reveals asensitivity of vascular CD39 transcription to several pro- and anti-inflammatory cytokines and to mechanical tension. In vivo study of potential role of CD39 (mice deficient for CD39 gene (Entpd1) and treatment with apyrase) in Angiotensin-II model of hypertension was also carried out. All these data suggest that a decrease in circulating and vascular CD39 may contribute to vascular changes associated with hypertension.

Une hyperactivation de la prolifération des cellules musculaires lisses vasculaires (CMLV) contribue à la pathogenèse des maladies des vaisseaux. Des travaux antérieurs suggèrent que l’augmentation de l'adénosine monophosphate cyclique (AMPc) inhibe la prolifération des CMLV. Provoquer une augmentation d’AMPc préviendrait aussi certaines maladies vasculaires qui sont associées à des altérations dans sa signalisation impliquant l'activité de la protéine kinase A (PKA). Des études ont démontré la contribution du facteur de transcription « early growth response protein-1» (Egr-1) dans la pathogenèse des maladies vasculaires et une surexpression d’Egr-1 a été rapportée dans des modèles d'athérosclérose et d'hyperplasie intimale. Divers agents vasoactifs contrôlent l'expression d’Egr-1 suivant des mécanismes qui ont fait l’objet de plusieurs études mais demeurent incomplètement élucidés. L'angiotensine-II (Ang-II) est l'un des principaux peptides vasoactifs impliqués dans la pathogenèse des maladies vasculaires. Une des voies de signalisation induite par l’Ang-II implique l’augmentation du calcium (Ca2+) intracellulaire. Celle-ci se produit par l’activation de l'entrée de calcium opérée par la relâche des réserves (SOCE) de Ca2+ réticulaire suite à l’activation du récepteur à l’inositol-3-phosphate (IP3R) et le recrutement ultérieur du complexe conducteur formé par la molécule d'interaction stromale 1 (STIM-1) et le canal Orai-1. Bien qu’il ait déjà été démontré que l’expression de l'Egr-1 est régulée par la signalisation calcique en réponse à plusieurs stimuli, l'implication du complexe STIM-1/Orai-1 dans l'expression d'Egr-1 dans la CMLV n’a jamais été étudiée. De même, la question de savoir si la signalisation induite par l'Ang-II conduisant à l'expression d'Egr-1 est modulée par l'AMPc n’a jamais été explorée. Par conséquent, les travaux menés dans cette thèse ont consisté à examiner le rôle de la signalisation du Ca2+ dans l'expression d'Egr-1 induite par l’Ang-II dans la CMLV avec une attention particulière portée sur le rôle joué par STIM-1 et Orai-1. En outre, nous avons examiné l'effet de l’augmentation de l’AMPc sur l'expression d'Egr-1 induite par l’Ang-II et étudié les voies de signalisation associées. Nos données montrent que l’inhibition du récepteur IP3R et du SOCE par le 2-aminoéthoxydiphénylborate atténue la libération de Ca2+ induite par l’Ang-II et ceci s’accompagne d’une baisse des niveaux d’expression de protéine et d’ARN messager de l’Egr-1. La stimulation de l’expression de l'Egr-1 a également été supprimée à la suite du blocage de la calmoduline et de la protéine kinase CaMKII. De plus, le blocage par interférence d’ARN de l’expression de STIM-1 et Orai-1 a atténué l'expression d'Egr-1 induite par l’Ang-II ainsi que la phosphorylation des protéines ERK et CREB. Par ailleurs, l'isoproterenol (ISO) et la forskoline (FSK), deux activateurs de l'adénylate cyclase ont atténué de manière dose-dépendante l'expression d'Egr-1 induite par l’Ang-II. Des réponses similaires ont été observées en utilisant des analogues non spécifique (dibutyryl-cAMP) et PKA-spécifique (Benzoyl-cAMP) de l’AMPc, ainsi qu'un inhibiteur à large spectre de l'activité phosphodiesterase intracellualaire (isobutylméthylxanthine). L'inhibition de l'expression d'Egr-1 induite par l’Ang-II s’accompagne d'une augmentation de l’activité de la PKA mesurée par la phosphorylation de la « phosphoprotéine activée par les vasodilatateurs (VASP) », et d’une diminution concomitante de la phosphorylation de la protéine ERK. Le blocage pharmacologique de la PKA a réduit la phosphorylation de VASP et restauré la phosphorylation de la protéine ERK ainsi que l'expression d'Egr-1 en présence de l’Ang-II. En résumé, nos données démontrent que la voie STIM-1/Orai-1 /Ca2+ médie l'expression de l'Egr-1 induite par l'Ang-II dans la CMLV et suggèrent que la suppression de la réponse à l’Ang-II menant à l’expression de l'Egr-1 peut expliquer les effets vasoprotecteurs de l’AMPc. En outre, ces travaux montrent que les mécanismes moléculaires de régulation de l’expression d’Egr-1 en réponse aux signaux externes culminent vers la modulation des cascades de signalisation en aval de la protéine ERK dans les CMLV. / Aberrant vascular smooth muscle cell (VSMC) proliferative responses contribute to the development of neointimal lesions. Cyclic adenosine monophosphate (cAMP) is believed to inhibit VSMC proliferation, and vascular diseases are associated with impairments in cAMP-induced signalling responses involving protein kinase A (PKA) signaling. An enhanced expression of the early growth response protein-1 (Egr-1), a zinc finger transcription factor, has been reported in models of vascular diseases and, a crucial role of Egr-1 in regulating the expression of genes implicated in neointimal formation leading to atherogenesis has been suggested. Various vasoactive factors have been shown to modulate Egr-1 expression in VSMC via mechanisms which remain to be completely understood. Angiotensin-II (Ang-II) is one of the key vasoactive peptides implicated in the pathogenesis of vascular diseases. Ang-II elevates intracellular calcium (Ca2+) through activation of voltage-gated calcium channels as well as store-operated calcium channels. The store-operated calcium entry (SOCE) involves an inositol-3-phosphate receptor (IP3R)-coupled depletion of endoplasmic reticular Ca2+ and a subsequent activation of the stromal interaction molecule 1 (STIM-1) /Orai-1 complex. Although Egr-1 has been demonstrated to be upregulated in a Ca2+-dependent fashion in response to several stimuli, the involvement of STIM-1/Orai-1-dependent signaling in Egr-1 expression in VSMC has never been addressed. Besides, whether Ang-II-induced signaling leading to Egr-1 expression is modulated by cAMP-dependent signaling pathway remains unexplored. Therefore, in the present studies, we have examined the role of Ca2+ signaling in Ang-II-induced Egr-1 expression in VSMC and investigated the contribution of STIM-1 or Orai-1. Additionnaly, we have examined the effect of cAMP on Ang-II-induced expression of Egr-1 and have investigated the associated signalling pathways. Pharmacological blockade of IP3R and SOCE by 2-aminoethoxydiphenylborate (2-APB) decreased Ang-II-induced Ca2+ release and attenuated Ang-II-induced enhanced expression of Egr-1 protein and mRNA levels. Egr-1 upregulation was also suppressed following blockade of calmodulin and CaMKII. Furthermore, RNA interference-mediated depletion of STIM-1 or Orai-1 attenuated Ang-II-induced Egr-1 expression, as well as Ang-II-induced phosphorylation of ERK1/2 and CREB. Moreover, isoproterenol (ISO) and forskolin (FSK), two respective receptor and non-receptor activators of adenylate cyclase, attenuated Ang-II-induced Egr-1 expression in a dose-dependent fashion. Similar responses were observed using non-specific (dibutyryl-cAMP) and PKA-specific (Benzoyl-cAMP) analogs of cAMP, as well as a broad spectrum inhibitor of intracellular phosphodiesterase activity (isobutylmethylxanthine). The inhibition of Ang-II-induced Egr-1 expression was accompanied by an increase in serine 157 phosphorylation of the vasodilator-activated phosphoprotein (VASP), a marker of PKA activity, and this was associated with a concomitant decrease in ERK phosphorylation. Pharmacological blockade of PKA using H89 decreased VASP phosphorylation, restored Ang-II-induced ERK phosphorylation and abolished ISO- and FSK-mediated inhibition of Ang-II-induced Egr-1 expression. In summary, our data demonstrate that STIM-1/Orai-1/Ca2+-dependent signaling pathways mediate Ang-II-induced Egr-1 expression in A-10 VSMC and suggest that PKA-mediated suppression of Ang-II-induced Egr-1 expression and phosphorylation of ERK may be among the mechanisms by which cAMP exerts its vasoprotective effects. In addition, our data supports the notion that stimuli-induced regulation of Egr-1 expression involves the participation of signaling cascades downstream of ERK in VSMC.

G protein-coupled receptors (GPCRs) are eukaryotic integral membrane proteins that perform transmembrane signal transduction. Due to their pivotal role in a wide range of essential physiological functions GPCRs represent a high proportion of all drug targets. High resolution X-ray structures of GPCRs are however underrepresented in the Protein Data Bank. This is due to their instability in detergent, low expression levels and the presence of misfolded receptors in many heterologous expression systems. The objective of this project was to engineer the angiotensin II type 1 receptor (AT1R), a human GPCR, to make it suitable for structural studies. It was determined that detergentsolubilised AT1R was thermostable with antagonist bound with an apparent Tm of ~45°C, which was sufficiently stable for purification without further thermostabilisation by rational mutagenesis. Two expression systems were then evaluated for large-scale production of AT1R, namely baculovirus-mediated expression in insect cells and mammalian expression in HEK293 cells. Radioligand binding assays showed that only the mammalian system produced sufficient quantities of active AT1R for structural studies. Expression in the mammalian system was further optimised to approximately 6 mg/L. An AT1R-GFP fusion was created to examine membrane localisation using confocal laser scanning microscopy, to assay expression levels, to select highly expressing monoclonal cell lines using fluorescence activated flow cytometry and to develop a fluorescence size-exclusion chromatographybased assay to examine the suitability of 12 different ligands for co-crystallization. AT1R was also engineered to facilitate crystallisation, including C-terminal truncations to remove predicted disordered regions and bacteriophage T4-lysozyme being added to the third intracellular loop to provide additional points of contact for crystallisation, which increased the apparent Tm by approximately 10°C. All modified versions of AT1R were assessed for expression, stability and monodispersity. Additionally a rapid western blotting based assay was developed for the detection of unfolded membrane proteins, which will have wide applicability in the field.

Neuropathic pain is one of the most debilitating disorders. Currently available treatments for neuropathic pain are still unsatisfactory as they have only limited treatment effect and patients may suffer from unwanted side effects. Mechanism-based approaches to neuropathic pain treatment are considered to be more effective. Therefore multiple studies are dedicated to study the pathophysiological mechanisms of neuropathic pain. One of the possible underlying mechanism that causes neuropathic pain is neuroinflammation. Recent studies suggested that angiotensin II ( main effector molecule of the renin-angiotensin system) via its receptors in the central nervous system may be involved in the neuroinflammatory processes. The aim of this study was to investigate the role of angiotensin receptor type 1 in the developement and maintenance of neuropathic pain induced in animal model. Spinal nerve ligation (L5) was used as a model of peripheral neuropathy. Our results showed that treatment with AT1R blocker losartan markedly reduced thermal hyperalgesia and reduced increased sensitivity to mechanical stimuli in the SNL-operated rats.This indicates a possibly significant role of AT1 receptors in the development of neuropathic pain, probably due to reduction of neuroinflammation in the nervous system. These findings...

No description available.

The angiotensin II (Ang II) type 1 receptor (AT1R) is involved in the regulation of blood pressure (through vasoconstriction) and water and ion homeostasis (mediated by interaction with the endogenous agonist). AT1R can also be activated by auto-antibodies (AT1R-Abs), which are associated with manifold diseases, such as obliterative vasculopathy, preeclampsia and systemic sclerosis. Knowledge of the molecular mechanisms related to AT1R-Abs binding and associated signaling cascade (dys-)regulation remains fragmentary. The goal of this study was, therefore, to investigate details of the effects of AT1R-Abs on G-protein signaling and subsequent cell proliferation, as well as the putative contribution of the three extracellular receptor loops (ELs) to Abs-AT1R signaling. AT1R-Abs induced nuclear factor of activated T-cells (NFAT) signaling, which reflects Gq/11 and Gi activation. The impact on cell proliferation was tested in different cell systems, as well as activation-triggered receptor internalization. Blockwise alanine substitutions were designed to potentially investigate the role of ELs in AT1R-Abs-mediated effects. First, we demonstrate that Ang II-mediated internalization of AT1R is impeded by binding of AT1R-Abs. Secondly, exclusive AT1RAbs- induced Gq/11 activation is most significant for NFAT stimulation and mediates cell proliferation. Interestingly, our studies also reveal that ligand-independent, baseline AT1R activation of Gi signaling has, in turn, a negative effect on cell proliferation. Indeed, inhibition of Gi basal activity potentiates proliferation triggered by AT1R-Abs. Finally, although AT1R containing EL1 and EL3 blockwise alanine mutations were not expressed on the human embryonic kidney293T (HEK293T) cell surface, we at least confirmed that parts of EL2 are involved in interactions between AT1R and Abs. This current study thus provides extended insights into the molecular action of AT1R-Abs and associated mechanisms of interrelated pathogenesis.

Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.